Background {#Sec1}
==========

Pleuroparenchymal fibroelastosis (PPFE) is characterised by pleural fibrosis and subpleural lung parenchymal fibroelastosis with or without upper lobe predominance \[[@CR1]--[@CR3]\]. Idiopathic PPFE has been included as a disease entity in the current guideline for classification of idiopathic interstitial pneumonias (IIPs), \[[@CR4]\] and PPFE is also postulated as radiological and pathological patterns \[[@CR2], [@CR5]\].

Radiological and pathological PPFE patterns the same as those for idiopathic PPFE were reported in diseases other than idiopathic PPFE, such as late-onset non-infectious pulmonary complications after hematopoietic stem-cell transplantation and/or chemotherapy (LONIPCs) \[[@CR6], [@CR7]\] and restrictive chronic lung allograft dysfunction after lung transplantation (LT) \[[@CR8], [@CR9]\]. These patterns can also exist with other radiological and pathological patterns such as usual interstitial pneumonia (UIP) \[[@CR3], [@CR5]\], nonspecific interstitial pneumonia (NSIP), organizing pneumonia, and bronchiolitis obliterans \[[@CR10], [@CR11]\]. However, it is unknown how radiological PPFE affects the clinical features and outcomes across interstitial lung diseases (ILDs), especially in severe cases.

Of ILDs with PPFE lesions, idiopathic PPFE and LONIPC are often progressive and fatal \[[@CR2], [@CR3], [@CR10], [@CR12], [@CR13]\], but the rate of disease progression is variable \[[@CR14]\]. Idiopathic pulmonary fibrosis (IPF) with pathological PPFE also tends to have worse survival than IPF without pathological PPFE \[[@CR5]\]. In idiopathic PPFE, LONIPC, and IPF, PPFE lesions are associated with restrictive impairment \[[@CR1]--[@CR3], [@CR5], [@CR15]\]. These findings suggest that PPFE lesions may have a significant effect on physiology and survival of ILD patients, whether the lesions are predominant (idiopathic PPFE/LONIPC) or concomitant with other predominant lesions such as IPF.

The objective of this retrospective study was to evaluate the clinical significance of radiological PPFE in patients with severe ILDs who are on a wait list for LT. We hypothesized that the presence of radiological PPFE would be associated with more severe physiological impairments and poorer survival.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Patients with fibrotic ILDs were identified from a prospective registry for cadaveric LT at Kyoto Universal Hospital between April 1, 2010 and August 31, 2015. Fibrotic ILDs included IPF, other IIPs, connective tissue disease-associated ILD (CTD-ILD), hypersensitivity pneumonia (HP), and LONIPCs. Registration criteria for the nationwide Japan Organ Transplant Network (JOTN) are 1) meeting the international listing criteria for LT, and 2) age \< 60 years for unilateral LT, and \< 55 years for bilateral LT. The algorithm for cadaveric donor lung allocation is based primarily on accrued time on the wait list, a situation which favors patients with slowly progressive diseases and disfavors patients with rapidly progressive diseases \[[@CR16]\]. Exclusion criteria for this study were 1) age \< 18 years old at the time of registration and 2) registration for a second LT. Patients with lymphangioleiomyomatosis, pulmonary, Langerhans cell histiocytosis, and sarcoidosis were excluded from analysis because these ILDs are not necessarily fibrotic and radiological PPFE did not accompany with these diseases in this cohort.

Clinical diagnoses for all patients were established at the time of evaluation for registration based on the multidisciplinary diagnoses at the individual referring institutes. For cases who had undergone LT, the final diagnoses were determined through a multidisciplinary discussion after LT at Kyoto University Hospital. idiopathic PPFE was diagnosed either by: 1) a multidisciplinary approach with pathological diagnosis of PPFE \[[@CR2], [@CR4]\], or 2) a radiological PPFE pattern (described below) without any alternative diagnosis.

Radiological evaluation {#Sec4}
-----------------------

Radiological PPFE patterns were defined as: *definite*, indicated by pleural thickening with associated subpleural fibrosis concentrated in the upper lobes, with involvement of lower lobes being less marked or absent (Fig. [1a](#Fig1){ref-type="fig"}), or *consistent*, indicated by upper lobe pleural thickening with associated signs of subpleural fibrosis present, but with distribution of these changes not concentrated in the upper lobes, or features of coexistent disease present elsewhere (Fig. [1b](#Fig1){ref-type="fig"}) \[[@CR2]\]. Both definite and consistent PPFE patterns were designated as indicating radiological PPFE.Fig. 1Radiological pleuroparenchymal fibroelastosis (PPFE) pattern on high-resolution computed tomography. **a**. Definite PPFE pattern. A 57-year-old male with idiopathic PPFE had definite PPFE. He received unilateral cadaveric lung transplantation after waiting for 266 days. Pathological PPFE was confirmed in the explanted lung. **b**. Consistent PPFE pattern. A 55-year-old male with IPF. Pleural thickening with associated signs of subpleural fibrosis is present in the upper lobes, while cystic lesions including honeycombing are seen in the lower lobes. Surgical lung biopsy showed pathological UIP and PPFE

All high-resolution computed tomography scans were reviewed for this study by two observers (K.T. and T.K. who had 22 and 17 years of experience, respectively) blinded to clinical information, and the presence or absence of a radiological PPFE pattern was recorded. Inter-observer disagreements were resolved by consensus.

Clinical variables {#Sec5}
------------------

Baseline clinical variables prospectively obtained and included in this analysis were demographics, serum biomarkers, standardized pulmonary function tests, six-minute walk test (6MWT), and arterial blood gas analysis. Arterial blood was collected with the patient in the supine position while breathing ambient air or supplementary oxygen as if at rest. The percutaneous oxygen saturation (SpO~2~) level was monitored continuously during the 6MWT.

Statistical analysis {#Sec6}
--------------------

Clinical features were summarized using medians (interquartile range \[IQR\]) and numbers (percentage) as appropriate. Wilcoxon and Fisher's exact tests were used for group comparisons. Survival time was calculated from the registration date to the JOTN until the patient's death, with patients right-censored at the time of cadaveric or living-donor lobar LT, or the last contact. The study population was divided into three categories defined by radiological PPFE and diagnoses: 1) idiopathic PPFE and LONIPC with radiological PPFE (all patients had radiological PPFE) (idiopathic PPFE/LONIPC), 2) other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE, and 3) fibrotic ILDs without radiological PPFE. For some analyses, the first category was further subdivided into idiopathic PPFE and LONIPC with radiological PPFE, making four categories. Kaplan-Meier curves and the log-rank test were used to demonstrate and compare overall survival time by radiological PPFE and the cohort divided into either three or four categories. Cox regression was performed to adjust survival analysis for age, sex, and the percentage of predicted forced vital capacity (%FVC). These variables were identified as potential confounders between radiological PPFE and survival, and between either three or four categories and survival. The percentage of predicted diffusion capacity of carbon monoxide (%DL~CO~) was not included in multivariable models because %DL~CO~ was available only in 74 patients (63%). Among data gained from the 6MWT, six-minute walk distance (6MWD) \< 250 m was included as a variable because it has been adopted in the listing criteria for LT \[[@CR17]\], although the 6MWT has not been standardized for the usage of oxygen when comparing different patients \[[@CR18]\]. Competing risk analysis establishing LT as a competitive outcome was also performed. All data analyses were performed using STATA/IC 14.2 for Mac (Stata Corp., Lakeway, TX, USA), with statistical significance set at *p* \< 0.05.

Results {#Sec7}
=======

Patients' characteristics {#Sec8}
-------------------------

One hundred eighteen patients with ILDs were identified from the Kyoto University Hospital registry for cadaveric LT. Radiological PPFE was diagnosed in 30/118 (25%) patients, with 12 (10%) diagnosed with definite and 18 (15%) diagnosed with consistent PPFE. All cases with radiological PPFE had traction bronchiectasis or volume loss of upper lobes, suggesting some clinical significance beyond the apical cap. Of these, 12 had LONIPC, with idiopathic PPFE (*n* = 9) as the second most common diagnosis (Table [1](#Tab1){ref-type="table"}). Of the 12 patients with definite PPFE, six had LONIPC, five had idiopathic PPFE, and one had CTD-ILD. Pathological diagnosis was achieved in 78/118 (66%) cases. Sixteen of the 30 cases with radiological PPFE (53%) had a pathological diagnosis, with histopathological PPFE confirmed in 12 (40%) of the radiological PPFE cases. In these 12 cases, histopathology showed predominant PPFE in four with idiopathic PPFE and one with LONIPC, coexistent PPFE and bronchiolitis in four with LONIPC; predominant UIP with coexistent PPFE in two with IPF, and predominant non-specific interstitial pneumonia with coexistent PPFE in one with LONIPC (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Four cases with radiological PPFE (two with other IIPs, one with IPF and one with CTD-ILD) did not have histopathological PPFE although a pathological diagnosis was available. None of these four cases underwent LT and only surgical lung biopsy samples were available for diagnosis (Additional file [1](#MOESM1){ref-type="media"}: Table S1). No case without radiological PPFE had histopathological PPFE. Baseline clinical characteristics are compared between patients with and without radiological PPFE in Table [2](#Tab2){ref-type="table"}. Radiological PPFE was associated with female gender, never-smoking, previous history of pneumothorax, lower body mass index (BMI), lower levels of serum Krebs von der Lungen-6 and lactate dehydrogenase, lower %FVC, higher %DL~CO~, less desaturation on the 6MWT, and hypercapnia.Table 1Diagnoses of study population (*n* = 118)With radiological PPFEWithout radiological PPFETotalDefiniteConsistentNumber30 (25.4)12 (10.2)18 (15.3)88 (74.6)LONIPC12 (40.0)6 (50.0)6 (33.3)2 (2.3)Idiopathic PPFE9 (30.0)5 (41.7)4 (22.2)0 (0.0)IPF4 (13.3)0 (0.0)4 (22.2)33 (37.5)Other IIPs2 (6.7)0 (0.0)2 (11.1)21 (23.9)CTD-ILD2 (6.7)1 (8.3)1 (5.6)25 (28.4)HP1 (3.3)0 (0.0)1 (5.6)7 (8.0)Data are presented as number (percentage)Abbreviations: *PPFE* plueroparenchymal fibroelastosis, *LONIPC* late-onset non-infectious pulmonary complication after hematopoetic stem-cell transplantation and/or chemotherapy, *IPF* idiopathic pulmonary fibrosis, *other IIPs* other idiopathic interstitial pneumonias than idiopathic pulmonary fibrosis, *CTD-ILD* connective tissue disease-associated interstitial lung disease, *HP* hypersensitivity pneumoniaTable 2Demographics, serum biomarkers, pulmonary function tests, six-minute walk test, arterial blood gas analysis, and treatment at the time of registration for lung transplantation (*n* = 118)With rPPFEWithout rPPFE*P*Number3088Demographics Age45.5 (37, 51)51 (43, 56)0.05 Male13 (43.3)58 (65.9)0.03 Ever-smoking8 (26.7)54 (61.4)0.001 Previous pneumothorax24 (80.0)23 (26.1)\< 0.001 Family history2 (6.7)21 (23.9)0.16 mMRC \[[@CR1]\]3 (3, 4)4 (3, 4)0.15 BMI15.9 (14.8, 17.2)21.5 (18.8, 25.1)\< 0.001Serum biomarkers KL-6, IU/L542 (402, 698)1460 (933, 2150)\< 0.001 LDH, IU/L186.5 (172, 212)229 (202, 271)\< 0.001Pulmonary function tests %FVC35.75 (22.6, 46.2)48.5 (37.6, 62.0)\< 0.001 %DLCO45.5 (37, 51)24.4 (17.4, 31.9)0.002Six-minute walk test Distance, meter375 (243, 500)333 (235, 454)0.36 Distance \< 250 m8 (26.7)26 (29.5)0.82 Lowest SpO~2~, %87.5 (81, 93)81 (76, 87)\< 0.001Arterial blood gas analysis PaO~2~, Torr77.8 (65.4, 86.6)74.05 (63.4, 87.9)0.73 PaCO~2~, Torr49.55 (45.6, 56.9)43.55 (40.7, 47.55)\< 0.001Treatment Corticosteroid11 (36.7)62 (70.5)0.002 IS agent3(10.0)40 (45.5)\< 0.001 Antifibrotic agent7 (23.3)39 (44.3)0.05 LTOT15 (50.0)63 (71.6)0.04Data are presented as number (percentage) or median (interquartile range)Abbreviations: *PPFE* plueroparenchymal fibroelastosis, *rPPFE* radiological PPFE, *mMRC* modified Medical Research Council dyspnea scale, *BMI* body mass index, *KL*-6 Krebs von der Lungen-6, *LDH* lactate dehydrogenase, %*FVC* the percentage to predicted forced vital capacity, %*DLCO* the percentage to predicted diffusion capacity of carbon monoxide, *SpO*~2~ percutaneous oxygen saturation, *PaO*~2~ arterial partial pressure of oxygen, *PaCO*~2~ arterial partial pressure of carbon dioxide, *IS* immunosuppressive, *LTOT* long-term oxygen therapy

Radiological PPFE association with survival {#Sec9}
-------------------------------------------

The median survival time of the 118 patients was 449 days (IQR: 215, 749). Thirty-five (30%) received LTs: cadaveric in 29 (unilateral in 24, and bilateral in five) and living-donor lobar in six. Of 83 patients who did not receive LT, 63 (76%) died. The causes of death were chronic respiratory failure in 35 (56%), acute exacerbation of ILDs in 15 (24%), and pneumonia/infection in three (5%).

Kaplan-Meier survival estimates are shown for patients with and without PPFE (Fig. [2a](#Fig2){ref-type="fig"}). The log-rank *p* value was not significant (*p* = 0.17). The Cox regression model adjusted for age, sex, %FVC, and 6MWD \< 250 m showed a marginal association of radiological PPFE with better survival (hazard ratio \[HR\], 0.51; 95% confidence interval \[95%CI\], 0.25--1.05, *p* = 0.07) (Table [3](#Tab3){ref-type="table"}, *Model 1*). Competing risk analysis showed similar results (Table [3](#Tab3){ref-type="table"}, *Model 1*).Fig. 2Kaplan-Meier survival estimates. Solid and dotted lines represent patients with and without radiological pleuroparenchymal fibroelastosis (PPFE) (*n* = 30; *n* = 88), respectivelyTable 3Multivariable Cox proportional hazards model for mortality (*n* = 118)*Transplant-censored*Competing analysis*Model 1*Hazard ratio95%CI*p* valueHazard ratio95%CI*P* valueRadiological PPFE0.51(0.25, 1.05)0.070.57(0.30, 1.12)0.10Age1.04(1.01, 1.07)0.011.03(1.01, 1.06)0.02Male1.05(0.61, 1.82)0.860.88(0.51, 1.52)0.65%FVC0.97(0.95, 1.00)0.030.98(0.96, 1.00)0.07Six-minute walk distance \< 250 m1.87(1.02, 3.43)0.042.36(1.33, 4.19)0.003*Model 2*Category Fibrotic ILDs^a^ without radiological PPFERef.----Ref.---- Idiopathic PPFE and LONIPC with radiological PPFE0.38(0.16, 0.90)0.030.41(0.21, 0.80)0.01 Other fibrotic ILDs with radiological PPFE0.96(0.35, 2.64)0.941.19(0.51, 2.78)0.69Age1.03(1.00, 1.07)0.021.03(1.00, 1.06)0.04Male1.01(0.58, 1.75)0.980.85(0.49, 1.47)0.56%FVC0.98(0.95, 1.00)0.030.98(0.97, 1.00)0.06Six-minute walk distance \< 250 m1.99(1.07, 3.70)0.032.51(1.39, 4.54)0.002*Model 3*Category Fibrotic ILDs without radiological PPFERef.----Ref.---- Idiopathic PPFE0.35(0.12, 1.04)0.060.39(0.20, 0.78)0.01 LONIPC with radiological PPFE0.42(0.12, 1.50)0.180.43(0.35, 2.64)0.15 Other fibrotic ILDs^a^ with radiological PPFE0.96(0.35, 2.64)0.941.19(0.51, 2.78)0.69Age1.04(1.00, 1.07)0.021.03(1.00, 1.07)0.04Male1.01(0.58, 1.75)0.980.85(0.58, 1.75)0.57%FVC0.98(0.95, 1.00)0.030.98(0.95, 1.00)0.06Six-minute walk distance \< 250 m2.00(1.07, 3.74)0.032.52(1.39, 4.54)0.003^a^Other fibrotic ILDs are IPF, other IIPs, CTD-ILD, and HPAbbreviations: *ILD* interstitial lung disease, *PPFE* plueroparenchymal fibroelastosis, *LONIPC* late-onset non-infectious pulmonary complication after hematopoetic stem-cell transplantation and/or chemotherapy, %*FVC* the percentage to predicted forced vital capacity, *IPF* idiopathic pulmonary fibrosis, *other IIPs* other idiopathic interstitial pneumonias than idiopathic pulmonary fibrosis, *CTD-ILD* connective tissue disease-associated interstitial lung disease, *HP* hypersensitivity pneumonia

Kaplan-Meier survival estimates are shown in Fig. [3a](#Fig3){ref-type="fig"} for cases divided into three categories by radiological PPFE and etiologies. The log-rank *p* value was not significant for idiopathic PPFE/LONIPC with radiological PPFE compared with fibrotic ILDs without radiological PPFE (the reference) (*p* = 0.10), or for other fibrotic ILDs with radiological PPFE compared to the reference (*p* = 0.99). However, the Cox regression model adjusted for age, sex, %FVC, and 6MWD \< 250 m showed an association of idiopathic PPFE/LONIPC with better survival (HR, 0.38; 95%CI, 0.16--0.90, *p* = 0.03; competing analysis: HR, 0.41; 95%CI, 0.21--0.80, *p* = 0.01) (Table [3](#Tab3){ref-type="table"}, *Model 2* and Fig. [3b](#Fig3){ref-type="fig"}). Survival for idiopathic PPFE/LONIPC with radiological PPFE was similar to that for other fibrotic ILDs with radiological PPFE (log-rank, *p* = 0.14). After adjustment for age, sex, %FVC, and 6MWD \< 250 m, idiopathic PPFE/LONIPC with radiological PPFE was marginally/significantly associated with better survival in comparison with other fibrotic ILDs with radiological PPFE (HR, 0.20; 95%CI, 0.04--1.11, *p* = 0.07; competing analysis: HR, 0.17; 95%CI, 0.04--0.76, *p* = 0.02).Fig. 3Kaplan-Meier survival estimates and estimated survival curves. **a**. Kaplan-Meier survival estimates. Solid, dotted, and short dashed lines represent idiopathic PPFE and LONIPC with radiological PPFE, other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE, and fibrotic ILDs without radiological PPFE (*n* = 21; *n* = 9; *n* = 88; *n* = 13), respectively. **b**. Estimated Cox survival curves adjusted for age, sex, and %FVC. Solid, dotted, and short dashed lines represent idiopathic PPFE and LONIPC with radiological PPFE, other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE, and fibrotic ILDs without radiological PPFE, respectively. Abbreviations: idiopathic PPFE, idiopathic pleuroparenchymal fibroelastosis; LONIPC, late-onset non-infectious pulmonary complication after hematopoetic stem-cell transplantation and/or chemotherapy; rPPFE, radiological PPFE; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; IIPs, idiopathic interstitial pneumonias; CTD-ILD, connective tissue disease-associated ILD; HP, hypersensitivity pneumonia

Figure [4a](#Fig4){ref-type="fig"} shows Kaplan-Meier survival estimates after dividing idiopathic PPFE/LONIPC with radiological PPFE into two subgroups: idiopathic PPFE and LONIPC with radiological PPFE. The log-rank *p* value was not significant for idiopathic PPFE compared to fibrotic ILDs without radiological PPFE (the reference) (*p* = 0.61), or for LONIPC with radiological PPFE compared to the reference (*p* = 0.09). The Cox regression model adjusted for age, sex, %FVC, and 6MWD \< 250 m showed marginal/significant associations of idiopathic PPFE with better survival (HR, 0.35; 95%CI, 0.12--1.04, *p* = 0.06; competing analysis: HR, 0.39; 95%CI, 0.20--0.78, *p* = 0.01) (Table [3](#Tab3){ref-type="table"}, *Model 3*, and Fig. [4b](#Fig4){ref-type="fig"}).Fig. 4Kaplan-Meier survival estimates and estimated survival curves. **a**. Kaplan-Meier survival estimates. Solid, dotted, short dashed, and long dashed lines represent idiopathic PPFE, other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE, fibrotic ILDs without radiological PPFE, and LONIPC with radiological PPFE (n = 9; n = 9; n = 88; *n* = 12), respectively. **b**. Estimated Cox survival curves adjusted for age, sex, and %FVC. Solid, dotted, short dashed, and long dashed lines represent idiopathic PPFE, other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE, fibrotic ILDs without radiological PPFE, and LONIPC with radiological PPFE, respectively

Discussion {#Sec10}
==========

In our cohort of fibrotic ILD patients registered for LT, 25% had radiological PPFE: the most common diagnosis in those with radiological PPFE was LONIPC, followed by idiopathic PPFE and IPF. Radiological PPFE was associated with a previous history of pneumothorax, lower BMI, lower %FVC, higher %DL~CO~, less desaturation on the 6MWT, and hypercapnia. Idiopathic PPFE/LONIPC with radiological PPFE was significantly associated with better survival than fibrotic ILDs without radiological PPFE, after adjustment for demographics, %FVC, and 6MWD. However, further studies are needed to confirm these findings and revise the registration criteria.

The impact of radiological PPFE on survival was different between idiopathic PPFE/LONIPC and other fibrotic ILDs. In idiopathic PPFE/LONIPC, PPFE lesions are predominant, and these lesions worsen at variable rates of progression \[[@CR14]\]. In other fibrotic ILDs with radiological PPFE, other lesions than PPFE, such as UIP and NSIP, are predominant, and they may influence survival independently from PPFE. Our results suggest that diagnosis of idiopathic PPFE may affect survival more strongly than the presence of radiological PPFE.

Reported survival time of patients with coexistent PPFE and other fibrotic ILDs is varied. UIP/possible UIP in the lower lobes did not affect survival of radiologically defined idiopathic PPFE patients \[[@CR19]\]. Biopsy-proven IPF with a concomitant histopathological PPFE lesion had worse survival than biopsy-proven IPF without such a lesion \[[@CR5]\]. In our cohort, on the other hand, patients with other fibrotic ILDs with radiological PPFE had survival time similar to those with fibrotic ILDs without radiological PPFE. This difference may be affected by the small number of cases with coexistent PPFE and other fibrotic ILDs (nine with UIP and PPFE in the biopsy-proven cohort \[[@CR5]\], and nine with other fibrotic ILDs (IPF, other IIPs, CTD-ILD, and HP) with radiological PPFE in our cohort). Future analyses of larger cohorts may be more definitive.

Radiological PPFE was associated with several clinical and physiological characteristics. History of pneumothorax, low BMI, and low %FVC were previously reported for patients with idiopathic PPFE, LONIPC, and IPF with pathological PPFE \[[@CR1], [@CR5], [@CR6], [@CR15], [@CR19]\]. Restrictive impairment present in patients with radiological PPFE may be partially caused by a flattened thoracic cage, in addition to lung parenchymal fibrosis. The thoracic cage is flattened and accompanied by disease progression in idiopathic PPFE \[[@CR20]\]. Lower BMI (thin body), and hypercapnia are possibly associated with this musculoskeletal change. Lower BMI has been associated with inspiratory muscle dysfunction in cystic fibrosis \[[@CR21]\], and inspiratory muscle training improves restrictive impairment and exercise capacity in adults with cystic fibrosis \[[@CR22]\]. Inspiratory muscle dysfunction may also have an effect on %FVC among patients with radiological PPFE.

Higher %DL~CO~ and less desaturation on the 6MWT in patients with radiological PPFE suggest that the lung parenchyma may be relatively preserved, compared to the severity of the restrictive and ventilatory impairments. Lower levels of serum biomarkers for lung injury (Krebs von der Lungen-6 and lactate dehydrogenase) are also consistent with less damaged parenchyma \[[@CR23]\]. The relatively milder parenchymal lesions may explain the better survival for patients with idiopathic PPFE/LONIPC, after adjustment for lower %FVC.

The diagnostic criteria for idiopathic PPFE have not been validated yet. Five of the nine patients with idiopathic PPFE in this cohort were diagnosed without the support of a pathological diagnosis, whereas the recent classification criteria for IIPs require a pathological diagnosis when diagnosing idiopathic PPFE \[[@CR4]\]. A surgical lung biopsy for the diagnosis of idiopathic PPFE is often unavailable because of patients' severe physiological impairment and high risks for refractory postoperative pneumothorax \[[@CR12], [@CR24]\]. Correlation between radiological and pathological diagnoses of PPFE seems acceptable in the literature of idiopathic PPFE \[[@CR2]\]. Thus, we diagnosed some cases of idiopathic PPFE without pathological diagnosis, after we carefully excluded any other diagnoses. In fact, no case without radiological PPFE was shown to have histopathological PPFE in our cohort when pathological diagnosis was available.

In addition, the diagnostic criteria for radiological PPFE have been defined only descriptively \[[@CR2]\]. Differentiation of radiological PPFE from apical cap may be difficult in some cases \[[@CR12]\]. A recent study included radiological progression of disease in the diagnostic criteria for idiopathic PPFE to exclude apical cap \[[@CR19]\]. All radiological PPFE cases in our cohort showed traction bronchiectasis or volume loss of the upper lobes, suggesting disease progression different from apical cap. However, more quantitative approaches may improve diagnostic accuracy and the predictive value of radiological evaluation for survival.

The present study had several limitations in terms of reduced generalizability. Our cohort excluded all patients who could not be registered for LT (age \> 60 for unilateral and \> 55 for bilateral LT, active infection, and other serious comorbidities). The prevalence of idiopathic PPFE/LONIPC with radiological PPFE in this cohort (18%) was higher than that of idiopathic PPFE in consecutive ILD patients undergoing SLB (5.9%) \[[@CR3]\] and that of LONIPC with PPFE in hematopoietic stem-cell and lung transplantation recipients (0.3% in hematopoietic stem-cell recipients, and 7.5% in lung transplantation recipients) \[[@CR25]\]. More PPFE cases may have been accumulated in our cohort of ILD patients waiting for LT than in other general ILD cohorts because there is no effective pharmacological therapy for idiopathic PPFE/LONIPC with radiological PPFE. As idiopathic PPFE/LONIPC with radiological PPFE patients are often younger than those with other fibrotic ILDs such as IPF, these patients are more likely to be referred to LT centers for registry.

Referral bias cannot be overemphasized. In particular, the average wait time for LT is longer than 800 days in Japan \[[@CR16]\]. Some physicians may have given up referring the most severe cases to LT centers, whether or not the cases have radiological PPFE. Two phenotypes of disease progression (rapid and slow) were reported in idiopathic PPFE \[[@CR14]\]. It is possible that our cohort mostly included patients with slowly progressive idiopathic PPFE, not another rapidly progressive phenotype, which can be associated with better survival of idiopathic PPFE and LONIPC with radiological PPFE. The algorithm for cadaveric donor lung allocation favoring patients with slowly progressive diseases may have exaggerated the trend toward better survival of this subgroup.

Although we used one of the largest cohorts of ILD patients registered for LT in Japan, only 30 patients with radiological PPFE were included. Predictors for survival of idiopathic PPFE and LONIPC and outcomes after LT should be also addressed \[[@CR26], [@CR27]\]. In addition, due to our retrospective design, changes in pulmonary physiology over time and treatment after registration could not be addressed.

Conclusions {#Sec11}
===========

In conclusion, we demonstrated that radiological PPFE was associated with a diagnosis of idiopathic PPFE/LONIPC, previous history of pneumothorax, lower BMI, lower %FVC, higher %DL~CO~, less desaturation on the 6MWT, and hypercapnia.

Idiopathic PPFE/LONIPC with radiological PPFE was significantly associated with better survival in ILD patients registered for LT, after adjustment for its association with lower %FVC and other covariates. Among several fibrotic ILDs with radiological PPFE, idiopathic PPFE and LONIPC, especially idiopathic PPFE may be associated with better survival than fibrotic ILDs without radiological PPFE. If validated, this suggests that idiopathic PPFE should be considered differently from other ILDs when the registration criteria for LT are revised.

Additional file
===============

 {#Sec12}

Additional file 1:**Table S1**. Sixteen radiological PPFE cases with a histopathological diagnosis. (DOCX 16 kb)
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95%CI

:   95% confidence interval
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:   Body mass index

BO

:   Bronchiolitis obliterans

CT-ILD

:   Connective tissue disease-associated interstitial lung disease

HP

:   Hypersensitivity pneumonia

HR

:   Hazard ratio

IIP

:   Idiopathic interstitial pneumonia

ILD

:   Interstitial lung disease

IPF

:   Idiopathic pulmonary fibrosis

IQR

:   Interquartile range

JOTN

:   Japan Organ Transplant Network

LAM

:   Lymphangioleiomyomatosis

LONIPC

:   Late-onset non-infectious pulmonary complication after hematopoietic stem-cell transplantation and/or chemotherapy

LT

:   Lung transplantation

NSIP

:   Nonspecific interstitial pneumonia

PLCH

:   Pulmonary Langerhans cell histiocytosis

PPFE

:   Pleuroparenchymal fibroelastosis

rPPFE

:   Radiological pleuroparenchymal fibroelastosis

UIP

:   Usual interstitial pneumonia
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